6Link M.L, Grossbard R.I, Fisher M, et al. Phase II pilot study of the safety and efficacy of Rituximab in combination with CHOP chemotherapy in patients with previously untreated intermediate or high-grade NHL. A.S.C.O., 1998,7.
7Riethmuloler G, Holz E, Schlimok G, et al. Monoclonal antibody therapy for resected Dukes'c colorectal cancer: Sevenyears outcome of a multicenter randomized trial, J clin Oncol, 1998,16(5)∶1988～1994.
8D. Salmon B. Leyland-Jones S. Shak V. et al. Addition of HERCEPTINTM(HUMANIZED, ANTI-HER2 ANT1BODY) to first line chemotherapy for her2 overexpressing metastatic breast concer (her2+/MBC) Markedly increases anticancer activiey:randomized, multional controlled phase III trial. A.S.C.O.,1998, 37.
9SG swisher, J.A.Roth, J Neumanitisd, et al. A denonriral mediated P53 gene transfer in patients with advanced no-small cell lung cancer. A.S.C.O., 1998, 1659.
10Parekh H.K. and Simpkins, H. The differential expression of cytokeratin 19 in cisplatin-senv stitive and resistant human ovarian adenocarcinoma cell and its association with drug sensitivity. Cancer Res, 1995, 55:5203～5206.
